Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway  by Bao, Shideng et al.
A R T I C L E
Periostin potently promotes metastatic growth of colon cancer
by augmenting cell survival via the Akt/PKB pathway
Shideng Bao,1,3 Gaoliang Ouyang,3 Xuefang Bai,1 Zhi Huang,3 Chaoyu Ma,1 Ming Liu,3 Rong Shao,1
Ryan M. Anderson,1 Jeremy N. Rich,2 and Xiao-Fan Wang1,*
1Department of Pharmacology and Cancer Biology
2 Department of Medicine
Duke University Medical Center, Durham, North Carolina 27710
3 The Key Laboratory for Cell Biology and Tumor Cell Engineering, The Ministry of Education of China, The School of Life
Sciences, Xiamen University, Fujian 361005, China
*Correspondence: wang0011@mc.duke.edu
Summary
Molecular mechanisms associated with tumor metastasis remain poorly understood. Here we report that acquired expres-
sion of periostin by colon cancer cells greatly promoted metastatic development of colon tumors. Periostin is overexpressed
in more than 80% of human colon cancers examined with highest expression in metastatic tumors. Periostin expression
dramatically enhanced metastatic growth of colon cancer by both preventing stress-induced apoptosis in the cancer cells
and augmenting endothelial cell survival to promote angiogenesis. At the molecular level, periostin activated the Akt/PKB
signaling pathway through the v3 integrins to increase cellular survival. These data demonstrated that the survival-
promoting function is crucial for periostin to promote tumor metastasis of colon cancer.
Introduction few of the large number of cancer cells shed from a primary
tumor ever form metastatic tumors (Chambers et al., 2002;
Weiss, 1990; Wong et al., 2001). As a consequence of thisThe process of malignant transformation involves the sequential
acquisition of a number of genetic and epigenetic alterations complexity, the metastatic process involves genetic changes
that underlie alterations in a variety of cellular functions for bothas a result of increasing genomic instability caused by defects
in checkpoint controls (Abraham, 2001; Hahn and Weinberg, cancer cells and the host environment, including the control
of cell proliferation, survival, motility, cell-cell adhesion, and2002; Hanahan and Weinberg, 2000; Nowak et al., 2002). In
humans, these alterations allow cancer cells to acquire the capa- interactions with the extracellular matrix (ECM) (Jacks and Wein-
berg, 2002; Liotta and Kohn, 2001; Weaver et al., 2002). Al-bilities to become self-sufficient in mitogenic signals, deregulate
the control of cell cycle, escape from apoptosis, and obtain though it is clear that those genetic changes often lead to alter-
ations in the expression pattern of specific genes, relatively littleunlimited replication potential via the reactivation of telomerase
(Artandi and DePinho, 2000; Blasco, 2002; Hanahan and Wein- is known about the nature of those molecular events that are
directly involved in the metastatic process.berg, 2000). Within a growing tumor mass, the genetic changes
during tumor progression also enable cancer cells to gain the As the second leading cause of death from malignancy in
the United States, colorectal cancer is the most common typeability to induce angiogenesis, invade neighboring tissues, and
metastasize to distant organs (Cavallaro and Christofori, 2000; of tumor to metastasize to the liver (Markowitz et al., 2002;
Takeda et al., 2002). Actually, metastasis accounts for the major-Chambers et al., 2002; Folkman, 2002).
The development of metastatic tumors consists of a series of ity of mortality associated with colorectal cancer, making an
effective treatment of this disease a complicated goal. Takingcomplex sequential events. Neoplastic cells within the primary
tumor mass have to journey through multiple steps, including advantage of the availability of both primary and metastatic
tumor samples from the same patients with metastatic colonintravasation into the circulation, survival in the circulation sys-
tems, arrest and extravasation into a new tissue, initiation and cancers, we searched for genes upregulated during metastasis
and report here the identification of periostin as a candidatemaintenance of growth, and reactivation of angiogenesis, in
order to successfully establish metastatic colonies in distant gene whose acquired expression by colon cancers is associated
with enhanced tumor metastatic growth and angiogenesis, pri-organs (Chambers et al., 2002; MacDonald et al., 2002). Hence,
S I G N I F I C A N C E
Metastases, rather than primary tumors, are responsible for most cancer deaths. To reduce malignancy death, it is critical to identify
and target proteins essential to the metastatic process. To this end, we identified periostin as a protein whose expression pattern is
intimately associated with the later stage of tumor progression. Through extensive functional analyses both in vitro and in vivo,
periostin was found to potently promote metastatic development of colon cancer. Given the key role periostin plays in tumor
metastasis, this secreted protein could serve as a potential therapeutic target for the control of metastatic growth of colon cancers.
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marily by promoting cell survival for both cancer cells and endo-
thelial cells.
Results
Periostin is differentially expressed in human primary
colon carcinomas and metastatic tumors
In order to identify genes that are potentially involved in promot-
ing late-stage progression of colon cancers, particularly metas-
tasis, we performed a series of differential cDNA display analy-
ses on mRNA samples isolated from normal colon tissue,
primary colon cancer, and metastatic tumor in the liver derived
from the same patient. One of the genes identified to have
a differential expression pattern among these three types of
samples was periostin (Figure 1A). Periostin is a secreted protein
that was originally isolated from osteoblasts and found to be
preferentially expressed in periosteum in bone tissue (Horiuchi
et al., 1999; Takeshita et al., 1993). Periostin contains an N-terminal
secretory signal peptide, followed by a cysteine-rich domain,
four internal homologous repeats, and a C-terminal hydrophilic
domain. The four internal repeats region of periostin shares a
homology with the axon guidance protein fasciclin I that is in-
volved in the development of nervous system in invertebrates
(Zinn et al., 1988).
To determine if the observed upregulation of periostin is a
common feature of colon cancer progression, we performed
Northern blot analysis on 29 pairs of matched normal colon
tissue and colon tumor samples. As shown in Figures 1B and
1C, periostin was found to be differentially overexpressed in
more than 80% of human primary colon cancer samples exam-
ined. Quantitative analysis indicated that two-thirds (20 of 29
cases) of examined primary colon carcinomas showed a tumor/
normal (T/N) ratio of periostin message expression higher than Figure 1. Differential expression of periostin in human primary and metastatic
colon carcinomas5-fold, with one-third of these primary tumors showing a T/N
A: Identification of periostin as a differentially expressed gene in the colonratio higher than 10-fold (Figure 1D). Furthermore, we found
metastatic tumor to the liver (M) and the matched primary colon tumor (T)that periostin was overexpressed in all cases of colon metastatic
versus normal colon tissue (N) from the same patient. 35S-labeled PCR cDNAtumors in the liver (Figure 1C). Importantly, the expression level
fragments from mRNA of these three types of samples from the same patient
of periostin in the hepatic metastases derived mostly from pa- were displayed based on their molecular sizes.
tients with relapses of their colon cancers was noticeably higher B: Northern blot analysis of periostin message expression in paired primary
colon tumor (T) and normal colon tissue (N) from the same patient. Totalthan that in the matched primary colon tumors from the same
RNA samples from matched tissues were probed with the human periostinpatients in 8 out of 9 cases examined (Figures 1C and 1E).
cDNA labeled with [-32P] dCTP. The same blot was probed with GAPDHQuantitative and statistical analysis indicated that the average for loading control.
T/N ratio of periostin message expression in those hepatic me- C: Higher expression level of periostin mRNA was found in the metastatic
tumor (M) in the liver than in the matched primary colon tumor (T) from thetastases was 2.6-fold of that in the matched colon primary
same patient in 5 out of 6 representative cases. Normal colon tissue (N)tumors, and the difference in periostin message expression be-
and normal liver tissue (L) were used as controls.tween the hepatic metastases and their matched colon primary
D: The number of colon primary carcinoma cases is plotted against the
tumors was significant (p  0.02) (Figure 1E). These results range of Tumor/Normal (T/N) ratios of hybridization signal for the matched
suggest that late-stage metastatic tumors express higher levels samples from the Northern blot analysis in B and C. Two-thirds of colon
carcinomas showed 5- to 15-fold periostin overexpression in contrast to theof periostin, which may play a role during the metastatic stage
matched normal colon tissues.of colon cancer progression.
E: The average Tumor/Normal (T/N) ratios of periostin expression betweenTo determine if the periostin protein is overexpressed in the liver metastases (MET) and the matched colon primary tumors (CPT)
colon cancer cells in the tumor tissues, we examined a series were quantified and plotted. Statistical analysis indicated that the periostin
message expression in the hepatic metastases (MET) derived mostly fromof matched tissue sections, including normal colon mucosae,
patients with relapses of their colon cancers was significantly higher (p primary colon tumors, and metastases in the liver, from the
0.02) than that in their matched colon primary tumors (CPT).same patients by immunohistochemical staining with an anti-
body against human periostin. The anti-periostin polyclonal anti-
body was purified through an affinity column and shown to
recognize specifically the periostin protein (Figure 3A). The im- as 9 cases of matched hepatic metastases derived mostly from
munohistochemical staining for periostin was performed on 25 patients with relapses of their colon cancers. As shown in Figure
cases of primary colon carcinomas, including 8 cases of stage 2, the immunostaining analyses indicated that high levels of
periostin were present in areas containing cancer cells of theII, 9 cases of stage III, and 8 cases of stage IV tumors, as well
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primary colon tumors (Figures 2B and 2C) and metastatic tumors
in the liver (Figure 2D). In contrast, periostin was undetectable in
normal colon mucosae (Figure 2A). Consistent with the message
expression analysis, more intense periostin staining was seen
in the hepatic metastases (Figure 2D) derived from the patients
with late relapses than that in the matched colon primary tumors
(Figure 2B). Overall, the majority (75%) of primary colon tumors
displayed prominent levels of periostin staining, whereas perios-
tin was hardly detectable in all matched normal colon tissues.
Quantitative analysis of the periostin immunohistochemistry
staining results with a SAMBA 4000 computerized image analy-
sis system with the Immuno 4.0 quantitative program indicated
that the average mean optical density (MOD) of periostin staining
in the stage II, stage III, or stage IV primary tumors is much higher
than that in their matched normal colon mucosae in each group,
respectively (p 0.01, Figure 2E). Furthermore, the quantitative
and statistical analysis revealed that the average MOD of perios-
tin protein staining in the hepatic metastases was found to be
2.7-fold of that in the matched colon primary tumors, and the
difference was significant (p 0.02, Figure 2F). Taken together,
these observations indicate that higher levels of periostin ex-
pression were associated with metastasized colon tumors.
Overexpression of periostin in colon cancer cells
potently promote metastatic tumor growth in the liver
To assess the functional significance of elevated periostin ex-
pression levels during the progression of colon cancer, we in-
vestigated whether stable overexpression of periostin in a hu-
man colon cancer cell line could alter its metastatic potential
in vivo when grown as xenografts in immune-compromised
mice. For this purpose, we selected a subline of the human
colon cancer cell line CX-1, CX-1NS, that expresses a very low
level of endogenous periostin and displays negligible metastatic
potential in vivo (Figure 3A and data not shown). A C-terminally
His-tagged periostin expression construct was transfected into
Figure 2. Immunohistochemical analysis of periostin expression in primary
the CX-1NS cells, and after drug selection, five individual stableand metastatic colon cancers
clones were isolated and verified for periostin expression. Three
The tissue sections of the primary colon cancers, their metastases in liver,
of those stable clones (A12, B08, and B19) and three vector-and the matched normal colon mucosae were immunostained with an
transfected controls (V03, V04, and V05) were used in subse-affinity-purified anti-periostin polyclonal antibody. The positive staining for
periostin protein was shown in a reddish-brown color. All sections were quent experiments. The expressions of the C-terminally His-
counterstained with Hematoxylin showing a blue color. tagged periostin in these three clones were verified with specific
A: Normal colon mucosae (N).
antibodies against His-tag and periostin (Figure 3A). Intriguingly,B: Stage II colon primary carcinomas (T II).
overexpression of periostin in CX-1NS cells led to a noticeableC: Stage IV colon carcinomas (T IV).
D: The matched hepatic metastases (MET) from patients with late relapses morphological change with an appearance of fibroblast-like cell
of colon cancers. Arrows indicate the carcinoma cancer cells. Two cases shape (Figure 3B) but did not result in an alteration in the rate
of matched samples as representative results are shown. of cell proliferation in vitro, as measured by the 3H-thymidine
E: The average mean optical density (MOD) of periostin staining form the
corporation assay (data not shown). To investigate the impact ofstage II (8 cases), stage III (9 cases), and stage IV (8 cases) primary cancers
periostin overexpression on tumor growth in vivo, we performedand their matched normal colon mucosae were statistically quantified and
plotted according to the disease stages. The average MOD of periostin xenograft assays via subcutaneous injection of the tumor cells
staining from the stage II, stage III, or stage IV colon carcinomas is signifi- into the nude mice to assess the potential differences in tumor
cantly higher than that from the matched normal colon mucosae in each
growth between the periostin-overexpressing and the vectorgroup, respectively (p  0.01).
control clones. As shown in Figure 3C, periostin overexpressionF: The average MOD (mean optical density) of periostin staining between
the hepatic metastases (MET) and the matched colon primary tumors (CPT) appeared to enhance the subcutaneous tumor growth over the
were compared and plotted. Statistical analysis indicated that the average control with an average ratio of less than 2-fold in tumor weight
MOD of periostin staining in the hepatic metastases (MET) derived mostly between the two types of cells. Thus, although periostin could
from patients with relapses of their colon cancers is significantly higher (p 
enhance tumor growth in the context of subcutaneous in vivo0.02) than that in their matched colon primary tumors (CPT). N, the matched
normal colon mucosae; L, the matched normal liver tissues. environment, the effect was moderate.
We next examined whether periostin overexpression could
affect the metastatic potential and growth of the cancer cells
in vivo. Equal numbers of cells (6  106/animal) of the three
periostin-producing CX-1NS clones or the three vector-trans-
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Figure 3. Characterization of periostin-overexpressing CX-1NS clones and
vector control clones
A: The conditional media from parental CX-1NS cells, three vector control Figure 4. Overexpression of periostin in colon cancer cells dramatically pro-
CX-1NS clones (V03, V04, V05), and three periostin-overexpressing CX-1NS moted tumor metastasis in the liver via intrasplenic injection as xenografts
clones (A12, B08, B19) were immunoblotted with -periostin, -His, -VEGF, in nude mice
-IL-8 antibodies. The expression levels of VEGF and IL-8 were shown un-
A: Representative results showing that injection of periostin-producing CX-changed among different clones. The whole-cell lysates from all samples
1NS colon cancer cells into spleen led to the formation of large metastaseswere blotted with -tubulin for loading control.
in the liver (T1-T5). However, no visually observable liver metastases wereB: Overexpression of periostin in CX-1NS cells resulted in cellular morphologi-
seen in the mice injected with the same number of vector-transfected CX-cal change with an appearance of fibroblast-like cell shape.
1NS control cancer cells (C1-C5). Large metastatic tumors derived from theC: The tumor weights of subcutaneous tumors derived from three clones of
periostin-producing CX-1NS colon cancer cells were seen to occupy almostperiostin-overexpressing CX-1NS cells (A12, B08, B19) and three clones of
the entire liver in some mice (T1, T2, T5). Arrows indicate the metastaticvector control CX-1NS cells (V03, V04, V05). The average ratio of tumor
tumors in the mouse liver (T1, T2) and the normal liver in the control miceweight between periostin-expressing CX-1NS tumor and vector control CX-
(C1, C2). The isolated livers from control mice (C3–C5) and the livers with1NS tumor is less than 2-fold.
huge metastatic tumors (T3–T5) are shown in the lower part of the figure.
B: The weights of metastatic tumors in the liver isolated from 16 animals
survived the procedure with injection of the periostin-overexpressing CX-
1NS cells and from 17 mice injected with the control cells were collected
fected controls were introduced into the nude mice via intra- and plotted together. Three periostin-overexpressing clones (A12, B08, and
splenic injection. Five weeks after the inoculation of tumor cells, B19) and three vector control clones (V03, V04, and V05) were used in these
experiments.the animals were sacrificed for the examination of metastatic
growth in the liver and other organs. Strikingly, multiple large
tumor metastases were detected in the livers of 15 out of 16
mice that survived the procedure with injection of the periostin-
upon examination with a dissecting microscope. The tumorproducing CX-1NS cells (Figure 4), with a majority of the meta-
weights of liver metastases isolated from each mouse of the twostatic tumors grown to the extent to occupy almost the entire
groups were plotted and shown in Figure 4B. Overexpression ofliver (T1, T2, T4, T5 in Figure 4A). In contrast, no visually observ-
periostin in colon cancer cells therefore strongly promoted tu-able metastatic tumors were found in the livers of the 17 control
mor metastatic growth in vivo, supporting a critical role formice injected with the control cells (C1-C5 in Figure 4A), al-
though 1–2 small tumor nodules were found in 6 of these mice periostin in the late stage of tumor progression.
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Overexpression of periostin enhanced vascularization
and reduced apoptosis in the growth of metastatic
tumors in the liver
Since the extent of the enhanced metastatic growth due to the
overexpression of periostin is far more dramatic than that of
the enhanced subcutaneous growth by the same cancer cells
(compare Figures 4B and 3C), we speculated that the periostin-
mediated metastatic tumor development in the liver was unlikely
only due to increased rate of tumor cell growth in vivo, and some
other cellular activities promoted by periostin protein may also
contribute to the fast metastatic development of the periostin-
overexpressing colon cancer cells in the liver.
During the process of dissecting the metastatic tumors, we
noticed that all metastases derived from the periostin-producing
CX-1NS cancer cells displayed high levels of hemorrhaging (T1-
T5 in Figure 4A), suggestive of elevated degrees of vasculariza-
tion. To address this possibility, we examined the blood vessel
density on the sections of those metastatic tumors by using
immunohistochemical staining with the antibody MECA32 (anti-
mouse panendothelial antigen), which recognizes an epitope
constitutively expressed on vascular endothelium of most tis-
sues including tumor nodules (Harmey et al., 2002). Quantitative
analysis of vessel density of three metastases for each CX-1NS
clone revealed that the blood vessel density of the metastatic
tumors derived from the periostin-overexpressing CX-1NS cells
is approximately 5-fold higher than that of the rare micrometas-
tases derived from the control cells (Figure 5A). As shown in
Figure 5B with the representative staining pattern of blood ves-
sels, the metastatic tumors derived from the periostin-producing
CX-1NS cancer cells were much more intensely vascularized
than the small metastatic nodules derived from the control can-
cer cells. These results strongly suggest that periostin secreted
by tumor cells may act in a paracrine manner to induce tumor
angiogenesis during metastatic growth, a finding consistent with
the notion that tumor angiogenesis is essential for the successful Figure 5. Analysis of blood vessel density and extent of apoptosis in the
metastatic tumor sectionsdevelopment of metastases (Chambers et al., 2002; Folkman,
2002; Takeda et al., 2002). A: Metastatic tumor sections from macrometastases derived from three
clones of periostin-overexpressing CX-1NS cells or from micrometastasesSince tumor metastatic growth is determined by the balance
derived from three clones of vector control cells were immunostained withof cell proliferation and programmed cell death, mechanisms
the MECA32 antibody to examine the presence of endothelial cells and
that promote cell survival or prevent apoptosis of cancer cells blood vessels. The blood vessel density in the metastatic tumors for each
would favor the establishment of metastatic tumor colonies. To clone was analyzed and quantified statistically. The average vascular den-
sity in the metastatic tumors derived from the periostin-overexpressing CX-test this, we examined the extent of cellular apoptosis in those
1NS cells was 5-fold of that in the micrometastases derived from the vectormetastatic tumors. As shown in Figure 5C, very few apoptotic
control CX-1NS cells.cells were found in the highly vascularized metastatic tumors
B: A representative result showing that abundant blood vessels (in reddish-
derived from the periostin-producing CX-1NS cells. In contrast, brown color) were detected in the metastatic tumors derived from the
significantly more apoptotic cells were detected in those small periostin-producing CX-1NS cells, but not in the small metastatic tumor nod-
ules found in 6 of 17 control mice injected with the vector-transfected CX-metastatic nodules derived from the vector-transfected CX-1NS
1NS cancer cells.control cells. These results indicate that periostin expression in
C: Metastatic tumor sections were analyzed with ApoAlert DNA fragmenta-
colon cancer cells led to a higher level of cellular survival or a tion assay to detect apoptotic cells. Many more apoptotic cells (in green
lesser extent of apoptosis that favors metastases development color) were present in the small metastatic nodules derived from the vector-
transfected CX-1NS control cells, but little apoptosis was seen in the largein vivo, an outcome that can at least partially be attributed to
metastases derived from the periostin-producing CX-1NS cancer cells.the induction of angiogenesis.
Periostin expression enabled cancer cells to
successfully establish metastases in the liver
by intraportal vein injection, and the formation of GFP-labeledTo further probe if the overexpression of periostin has a direct
micrometastases in the liver was examined on day 5 and dayimpact on the initial stage of micrometastatic colony formation,
10 after injection. On day 5, the density of micrometastases orwe introduced the green fluorescent marker GFP into the perios-
solitary cancer cells in the liver derived from the periostin/GFP/tin-producing and the control CX-1NS cells. Equal numbers of
CX-1NS cells and the vector/GFP/CX-1NS controls was notcells (6  106/animal) of the periostin/GFP/CX-1NS clones or
the vector/GFP/CX-1NS controls were injected into nude mice significantly different as revealed by the presence of approxi-
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Figure 6. Significant differences in the ability to establish micrometastases
by the periostin/GFP/CX-1NS cells and the vector/GFP/CX-1NS control cells
in the liver of nude mice via intraportal injection
A and B: On day 5 after injection, no significant difference was observed
in the number and the size of the GFP-labeled micrometastases derived
from the periostin/GFP/CX-1NS cells (A) and from the vector/GFP/CX-1NS
cells (B) in the liver sections.
C and D: On day 10 after injection, significant differences were seen in the
number and the size of metastases derived from the periostin/GFP/CX-1NS
cells (C) and the vector/GFP/CX-1NS cells (D).
mately equal numbers of GFP fluorescent-labeled colonies or
single cells on liver sections (Figures 6A and 6B). On day 10,
however, we found that those metastases derived from perios-
tin/GFP/CX-1NS cells had grown to form larger metastatic colo-
nies (Figure 6C), although the overall number of metastases
was reduced. In contrast, those micrometastatic nodules de- Figure 7. Periostin promoted cellular survival for both CX-1NS colon cancer
rived from the vector/GFP/CX-1NS cells had failed to grow in cells and HMVECs under various stress conditions
size and the number of the micrometastases significantly de- A–C: Periostin expression in CX-1NS cells enhanced cellular survival under
conditions of serum depletion (A) and hypoxia induced by DFO (Deferoxa-creased (Figure 6D), implicating the failure to establish metasta-
mine) treatment (B) and protected them from undergoing anoikis (C). Re-ses once seeded in the liver. These data suggest that periostin
sults in A and B were obtained from quantification of three independentexpression did not significantly affect the initial formation of
experiments with three periostin-overexpressing clones and three vector
micrometastases, but played a crucial role in the subsequent control clones.
establishment of metastases in the new microenvironment in D–F: Incubation of HMVECs with the recombinant periostin (100 ng/ml) in-
creased cellular survival under conditions of serum depletion (D) and hyp-the liver.
oxia induced by DFO treatment (E), and protected them from anoikis in-
duced by the loss of cell attachment (F). To prevent adhesion, CX-1NS cellsPeriostin augmented cellular survival for colon and HMVECs were cultured on Petri dishes coated with PolyHema in serum-
carcinoma cells and endothelial cells under free medium. Results in D and E were quantified from three independent
experiments with purified periostin protein.conditions of growth stress
To explore the mechanism at the cellular level by which periostin
promotes tumor metastasis and growth, we examined the bio-
logical effects of periostin on both tumor cells and the human
ures 7D and 7E), which is compatible with the survival-promot-microvessel endothelial cells (HMVECs) that are known to play
ing effect induced by the potent angiogenic factor VEGF. Inan essential role in tumor angiogenesis under in vitro conditions
addition, we observed that periostin overexpression or the pres-that mimic the cellular stress inside metastatic tumors, such
ence of the recombinant periostin protected both tumor cellsas hypoxia and nutrient deprivation with serum depletion. As
and HMVECs from undergoing anoikis, the cell death inducedshown in Figures 7A and 7B, results from three independent
by loss of adhesion. When the control CX-1NS cells were cul-experiments with three clones (A12, B08, and B19) revealed that
tured in the Petri dish coated with PolyHema to prevent adhe-periostin-producing CX-1NS cells were indeed more resistant to
sion, they displayed massive anoikis in 5 days (Figure 7C, left).serum starvation and hypoxia in comparison to three clones of
However, most periostin-producing CX-1NS cells survived un-the control cells (V03, V04, and V05). Similarly, the recombinant
der the same condition (Figure 7C, right). Similar results wereperiostin was shown to enhance the ability of HMVECs to survive
under the same serum depletion and hypoxic conditions (Fig- obtained with HMVECs untreated or treated with 100 ng/ml of
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recombinant periostin for 4 days (Figure 7F). Taken together,
these data demonstrate that periostin could act to promote
cellular survival for both tumor cells and endothelial cells under
stress conditions that are commonly associated with the meta-
static tumor and a fast-growing tumor mass, such as hypoxia,
nutrient depletion, and loss of adhesion.
Periostin activated the Akt/PKB pathway via the v3
integrins to promote cellular survival
To explore the molecular mechanism by which periostin pro-
motes cellular survival, we examined the potential effect of
periostin on the activities of several known cellular survival path-
ways. To this end, we found that periostin expression or treat-
ment with the recombinant periostin in both CX-1NS cancer
cells and HMVECs led to activation of the Akt/PKB signaling
pathway as measured by the specific phosphorylation of Akt1/
PKB on Ser473. As shown in Figure 8A, Ser473 phosphoryla-
tion that indicates the activation of Akt/PKB pathway (Nicholson
and Anderson, 2002) was readily detected in the periostin-pro-
ducing CX-1NS cells, but not in the parental and vector-trans-
fected CX-1NS cells under the serum-free condition. Similarly,
treatment of HMVECs with 100 ng/ml periostin under the serum-
free condition led to Akt1/PKB phosphorylation on Ser473
(Figure 8B).
A recent report indicated that periostin could bind to the
v3 and the v5 integrins in ovarian cancer cells (Gillan et al.,
2002). To probe if the integrins are involved in the mediation
of periostin action, we pre-incubated the CX-1NS cells and
HMVECs with antibodies against each of these two integrins
and measured the phosphorylation of Akt1/PKB on Ser473
induced by the presence of periostin. As shown in Figures 8A
and 8B, the results indicate that activation of the Akt/PKB sur-
Figure 8. Periostin activated the Akt/PKB survival pathway through the v3vival pathway by periostin is mediated primarily through the v3
integrins to enhance cellular survival
integrins signaling pathway, since the antibody against the v5
A: The phosphorylation of Akt1/PKB on Ser473 was detected in periostin-integrins did not block the phosphorylation event in the producing CX-1NS cells (lane 3), but not in the parental (lane 1) and the
HMVECs. These results indicate that at the mechanistic level, vector-transfected CX-1NS (lane 2) cells under the serum depletion condi-
tion. This specific phosphorylation event was blocked by the presence ofthe binding of periostin to the v3 integrins leads to activation of
an antibody against the v3 integrins (lane 4).the Akt/PKB cellular survival pathway, consequently protecting
B: Phosphorylation of Akt1/PKB on Ser473 was induced by the recombinant
both tumor cells and endothelial cells from stress-induced cell periostin in HMVECs in the basic medium without serum. This specific phos-
death and promoting angiogenesis and metastasis. phorylation event induced by periostin was blocked by the antibody
against the v3 integrins (lane 3) but not by an antibody against the v5To further confirm that periostin activates the Akt/PKB ki-
integrins (lane 4).nase to promote cellular survival, we used two approaches to
C and D: Overexpression of PTEN in CX-1NS cells (C) or HMVECs (D) abolished
block the Akt/PKB function and then examined the effect on the the survival promotion or protection effect of periostin under the condition of
periostin-mediated enhancement in cell survival under stress serum depletion stress. PTEN overexpression was mediated via the retrovirus
infection. The control group was infected with the retrovirus containingcondition. For this purpose, we either overexpressed PTEN, a
backbone vector without the PTEN cDNA. The result was quantified fromwell-established negative regulator of the Akt/PKB pathway, to
three independent experiments.
suppress the phosphorylation of Akt/PKB phosphorylation and E and F: The Akt/PKB specific inhibitor (15 M 1L-6-Hydroxymethyl-chiro-
inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate) abrogated the survivalinactivate its function (Davies et al., 1999; Nicholson and Ander-
promotion ability of periostin in both CX-1NS cancer cells (E) and theson, 2002), or directly blocked Akt/PKB kinase activity by treat-
HMVECs (F) under serum depletion condition. In the absence of the Akt/ing cells with a specific Akt/PKB inhibitor, 1L-6-Hydroxymethyl- PKB inhibitor, periostin protein (100 ng/ml) exhibited the survival promotion
chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate (Hu et effect on both CX-1NS cells and HMVECs under serum depletion. In contrast,
incubation of CX-1NS cells or HMVECs with the Akt/PKB inhibitor abolishedal., 2000). As shown in Figures 8C and 8D, overexpression of
the protection effect of periostin.PTEN in CX-1NS colon cancer cells or HMVECs, as well as
incubation of those cells with 15 M of the specific Akt/PKB
inhibitor, abrogated the survival promotion or protection effect
of periostin in both cell types under the condition of serum Discussion
depletion stress. These data firmly established that periostin
protects cells from stress-induced death by activating the Akt/ The findings presented here demonstrated the validity and fruit-
fulness of our approach in identifying specific genes whosePKB survival pathway.
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altered expression pattern is intimately associated with later development of metastases (Chambers et al., 2002; Hynes,
stages of tumorigenesis, particularly metastasis. Through exten- 2003). Our results indicate that the presence of periostin did
sive functional analyses, one of the candidate genes identified not significantly affect the initial formation of micrometastases in
by this approach, periostin, was shown to promote later stages the liver in the animal models, but that it did stimulate metastatic
of tumor progression. A colon cancer cell line with a low meta- growth and development at later stage by promoting cancer
static potential engineered to overexpress periostin displayed cell survival and inducing angiogenesis. Thus, periostin secreted
a striking phenotype of greatly accelerated tumor metastatic by the tumor cells functions to promote the survival of tumor
growth as xenografts in the animal model system of metastasis. cells, in addition to playing a role in a paracrine manner to
The underlying mechanism of periostin-mediated promotion of augment the survival of endothelial cells and induce neovascu-
tumor metastasis is largely associated with the ability of perios- larization, an activity consistent with the notion that enhanced
tin to enhance cellular survival for both cancer cells and endo- survival of endothelial cells within tumors is critical for the suc-
thelial cells under stress conditions. The discovery of a link cessful development of tumor angiogenesis (Brooks et al., 1994;
between periostin and the v3 integrin-Akt/PKB signaling path- Scatena and Giachelli, 2002; Stupack and Cheresh, 2002). The
way provides a molecular explanation for the prosurvival activity dual functions of periostin on the two types of cells within the
of periostin in the context of tumor progression through the tumor mass may contribute to the rapid development and estab-
successful development of angiogenesis and establishment of lishment of metastases in the liver. Since this protein is intimately
metastatic colonies, as both the v3 integrins and the Akt/ involved in the critical rate-limiting steps of tumor metastatic
PKB pathway have been implicated to play important roles in process, periostin could be a potential target for the develop-
promoting cell survival and tumorigenesis (Brooks et al., 1994;
ment of novel treatment for metastatic colon cancers.
Nicholson and Anderson, 2002; Stupack and Cheresh, 2002).
At the mechanistic level, it is not surprising that we found
In addition to playing a critical role in the progression of
periostin to exert its effect via the integrins, as a large numbercolon cancers, periostin appears to be involved in other human
of studies have demonstrated that interactions between integ-cancers as a recent report showed that serum levels of periostin
rins on the surface of tumor cells and adhesion molecules inare elevated in patients with bone metastases from breast can-
the ECM microenvironment are extremely important for tumorcer (Sasaki et al., 2003) and periostin expression is upregulated
cell migration, survival, and growth in different anatomical loca-in ovarian cancers (Ismail et al., 2000). In a separate study, we
tions to form distant metastases (Green and Evan, 2002; Jackshave found that periostin was overexpressed by a majority of
and Weinberg, 2002; Liotta and Kohn, 2001; Weaver et al.,breast cancers examined by genearray analysis (data not
2002). The ECM-integrin interactions are not only critical forshown). Interestingly, ig-h3, a secreted RGD sequence-con-
tumor cell survival, but also important to trigger intracellulartaining protein that shares a significant structural homology with
signaling and activation of certain genes that lead to tumor cellperiostin, was also found by SAGE analysis to be differentially
proliferation during metastatic growth (Meredith and Schwartz,overexpressed in human colon cancer (Zhang et al., 1997), indi-
1997). In addition, the interactions between cell surface integrinscating that ig-h3 may be similarly involved in promoting tumori-
and ECM components are also essential for the survival ofgenesis. However, ig-h3 does not contain the sequence ho-
endothelial cells and the formation of blood vessels within themologous to the C-terminal hydrophilic domain in periostin,
tumor mass (Brooks et al., 1994; Scatena and Giachelli, 2002;suggesting that functional differences may exist between the
Stupack and Cheresh, 2002). The life and death decision at thetwo proteins during tumor development.
cellular level is controlled by the proper cell-matrix interactionsTumor metastatic process consists of multiple and complex
steps, all of which must be successfully completed to give rise to (Jacks and Weinberg, 2002; Stupack and Cheresh, 2002). Thus,
the outgrowth of metastatic tumors in a new organ environment tumor cells that are unable to adapt to the new microenviron-
(Chambers et al., 2002; Folkman, 2002). During this process, ment in distant sites lose their ability to form metastases. With-
cancer cells have to overcome many types of stresses such as out acquiring specific genetic changes, most cancer cells reach-
hemodynamic shearing, loss of adhesion, nutrient depletion, ing different anatomical tissues are unlikely to survive in the
hypoxia, and accumulation of wastes that may all induce cell new ECM environment and are unable to initiate metastatic
death. Furthermore, it has been recognized that metastasis is growth, providing a plausible explanation for the low efficiency
a relatively inefficient process (Chambers et al., 2002; Luzzi et of metastatic process. In this regard, acquired expression of
al., 1998; Weiss, 1990). Although early steps in the hematoge- periostin and similar types of proteins may enable tumor cells
nous metastatic process from the entry of cancer cells to the to thrive in the new environment of distant organs and grow as
bloodstream until their extravasation into secondary organs are successful metastatic colonies.
remarkably efficient, subsequent steps associated with the es-
tablishment of metastases are completed inefficiently, with only Experimental procedures
a small number of cancer cells being able to initiate the formation
Differential cDNA display and Northern blot analysisof micrometastases in the secondary site, and an even smaller
Differential cDNA display and Northern blot analysis were performed assubset of those micrometastases evolving into macroscopic
described previously (Bao et al., 1998). Poly(A) mRNA used for the displaymetastases (Chambers et al., 2002; MacDonald et al., 2002;
was purified from total RNA by using Oligotex mRNA kit (Qiagen, Valencia,Naumov et al., 2002). Two critical aspects that allow micromet-
CA). The total RNA was extracted from colon primary or metastatic tumorsastases to progress into established metastatic colonies are the
or normal colon tissues (surgical specimens) by Tri-reagent (Leedo Medical
initiation of angiogenesis within the micrometastases and the Lab., Houston, TX). Surgical specimens of metastatic tumors and primary
prevention of cancer cell death that tips the balance favoring colon carcinomas at different stages were obtained from Division of Tumor
cell proliferation over apoptosis. The ability for cancer cells to Pathology, Xiamen First Hospital. Hybridization signals from Northern blot
were quantified and analyzed as previously described (Barnard et al., 1992).survive and grow in the distant organ is critical for the successful
336 CANCER CELL : APRIL 2004
A R T I C L E
Immunohistochemical staining and analysis of tumor each clone. 4 weeks after injection, mice were sacrificed and examined for
the growth of subcutaneous tumors.vascular density
Paraffin-embedded colon tumor and normal tissue sections were processed
Apoptosis assayfor antigen retrieval by heating in 10 mM sodium citrate (pH 6.0) at 95C
To examine the apoptotic events in the liver metastases derived from thefor 20 min. Then, sections were immunostained with an affinity-purified
periostin-producing CX-1NS cancer cells or the vector-transfected CX-1NSpolyclonal antibody raised against the recombinant human periostin protein.
control cells, frozen sections of the metastatic tumors were analyzed byThe immunostaining was performed with an ABC staining system (Vector
using the ApoAlert DNA fragmentation assay kit (BD-Clontech). The assayLaboratories, Burlingame, CA) using avidin-biotinylated-peroxidase detec-
was performed according to the user manual. Apoptotic cells appear intion method. The immunostaining to detect the blood vessels in the metasta-
green color with the FITC filter under a fluorescent microscope.ses of mouse liver with the MECA32 antibody (rat anti-mouse panendothelial
antigen; Pharmingen, San Diego, CA) was performed as described (Harmey
Periostin protein expression and purificationet al., 2002). The blood vessel density in tumor was calculated and quantified
The recombinant periostin protein was expressed in the insect cells usingas previously described (Filleur et al., 2001; Vermeulen et al., 1996).
the baculovirus expression system (Invitrogen). A hexa-histidine tag wasTo insure the comparability of the periostin immunohistochemical stain-
added to the C terminus of the human periostin. The detailed method caning, a common reference standard was included to serve as an internal or
be found in the Supplemental Data (http://www.cancercell.org/cgi/content/intra-assay control in every slide as previously described (Sompuram et al.,
full/5/4/329/DC1).2002a, 2002b). The detailed method is described in the Supplemental Data
(http://www.cancercell.org/cgi/content/full/5/4/329/DC1).
Anoikis assay
To determine the effect of periostin on cell survival under anoikis-inducingQuantitative and statistical analysis of periostin
condition, cells were prevented from adhering to the plastic dishes by cultur-immunohistochemical staining
ing them in Petri dishes coated with PolyHema (Sigma, St. Louis, MO) as de-The quantitative analysis of the immunohistochemical (IHC) staining for peri-
scribed previously (Zhu et al., 2001). The detailed assay is described in theostin expression in tumor tissues was performed as previously described
Supplemental Data (http://www.cancercell.org/cgi/content/full/5/4/329/DC1).(Mady and Melhem, 2002; Ang et al., 2002). The staining of each tissue was
analyzed to determine the Mean Optical Density (MOD), which represents
Cell survival assay under hypoxia and serum-depletion conditionsthe concentration of the stain as measured per positive pixels. The detailed
Periostin-producing CX-1NS cells and the vector-transfected CX-1NS cellsmethod can be seen in the Supplemental Data (http://www.cancercell.org/
were grown in the normal medium until 60%–70% confluency. Then, theycgi/content/full/5/4/329/DC1).
were incubated with serum-free medium or treated with 100 M DFO (Defer-
oxamine; Sigma) to mimic hypoxia (Bianchi et al., 1999) for different timeCell culture and transfection
points as indicated, and the numbers of survival cells at different time pointsCX-1NS cells were cultured in DMEM growth medium (Invitrogen Corp.,
were analyzed and counted. The results were quantified from three indepen-Carlabad, CA) supplemented with 10% FBS and antibiotics. The human
dent experiments with three periostin-expressing CX-1NS clones and three
microvascular endothelial cells HMVECs (Clonetics, Walkersville, MD) were
vector control clones. For endothelial cells, after HMVECs were grown in
maintained in endothelial growth medium (EGM-2-MV; Clonetics) supple-
the growth medium until 60%–70% confluency, the cells were incubated
mented with 5% FBS (Clonetics). Cell transfections were performed using
with serum-free basic medium containing 100 ng/ml of periostin, VEGF, or
FuGene 6 reagent (Roche) according to the manufacture’s instruction.
BSA, or were treated with 100 M DFO (Sigma) in the medium containing
100 ng/ml of periostin, VEGF, or BSA for different time points as indicated,
Generation of periostin-producing colon cancer cells
and the surviving cells were analyzed and counted at different time points. At
To construct a periostin expression plasmid, the full open reading frame of least three independent experiments were performed to obtain the statistical
human periostin cDNA was cloned into pcDNA3.1 mammalian expression results.
vector (Invitrogen) with a hexa-histidine tag at COOH terminus of periostin
protein. Then, the periostin/pcDNA3.1 plasmid or the vector alone was intro- Western blot analysis
duced into CX-1NS colon cancer cells, and the stable clones were obtained For the detection of secreted periostin protein, periostin-producing cells or
by G418 selection (950 g/ml) in the culture medium. 3 of 5 periostin- control cells were grown in normal medium until 80% confluency and then
expressing clones and 3 of 6 control clones were chosen for the subsequent cultured in the serum-free medium for 24 hr. The serum-free conditional
experiments. In order to observe the initial formation of the micrometastases medium were collected and analyzed by immunoblot with a specific anti-
in the liver, the GFP plasmid (pEGFP; Clontech, Palo Alto, CA) was introduced periostin polyclonal antibody, anti-His antibody (H-15 or H-3; Santa Cruz
into two of those periostin-producing CX-1NS clones and two of the Biotechnology), anti-VEGF polyclonal antibody (Ab-4, Calbiochem, La Jolla,
pcDNA3.1 vector-transfected control clones to stably express the green CA), and anti-IL-8 mAb (B2, Santa Cruz). The specific anti-periostin antibody
fluorescent marker. was generated by immunizing the rabbits with recombinant periostin protein
and purified through an affinity column. For the detection of Akt and other
Xenograft assays in nude mice proteins, cell lysates were analyzed by immunobloting with the anti-Akt1/
To examine whether periostin expression in colon cancer cells affects meta- PKB (#9272) and anti-pS473-Akt1/PKB (#9271) rabbit polyclonal antibod-
static growth in the liver, periostin-expressing CX-1NS cells (6  106/animal) ies (Cell Signaling Technology Inc., Beverly, MA). Anti-v3 mAb (LM609;
were injected into female nude mice (Charles River, Raleigh, NC) via intra- Chemicon Inc., Temecula, CA) and anti-v5 mAb (PIF6; Chemicon) were
splenic injection as previously described (Khatib et al., 1999). The control used at 10 g/ml for the functional blocking experiments.
groups were injected with the same number of vector-transfected CX-1NS
cancer cells. Three periostin-overexpressing clones (A12, B08, and B19) and PTEN retrovirus and the Akt inhibitor
three vector control clones (V03, V04, and V05) were used in this experiment. The PTEN retroviral construct was generated by inserting the PTEN full-
Seven to eight mice were injected for each clone. The mice that survived length open reading frame into the retroviral backbone vector pBabe with
the procedure were sacrificed 5 weeks after injection and examined for a puromycin selection marker. The production of the retrovirus and the
metastases development. To detect the GFP-labeled micrometastases for- infection of cells for protein overexpression were performed as previously
mation, periostin/GFP/CX-1NS cells (6  106/animal) or the same number described (Rich et al., 2003). Control cells were infected with retrovirus
of the vector/GFP/CX-1NSs were injected into nude mice by intraportal vein containing the backbone vector but without the PTEN cDNA. The Akt/PKB-
injection. On day 5 and day 10 after injection, liver sections of mice from both specific inhibitor (1L-6-Hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-
groups were checked to detect GFP micrometastases under a fluorescent octadecylcarbonate) that has been shown to potently inhibit Akt/PKB (Hu
microscope. For the subcutaneous injection, three clones of periostin- et al., 2000) was obtained from Calbiochem. 15 M Akt/PKB inhibitor was
expressing CX-1NS cells (5  106/animal) and three clones of vector control used to treat CX-1NS cells and HMVECs for the indicated experiments
according to the manufacturer’s instructions.CX-1NS cells (5  106/animal) were injected to SCID mice with 5 mice for
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